BioMérieux Shares Plunge 17% to Four-Year Low Following Warning

Quarterly Sales Decline and Revised Forecasts

BioMérieux published a quarterly revenue of 984 million euros on April 23, marking an organic contraction of 3.9%. The company cited a sluggish respiratory season and an uncertain macroeconomic environment as reasons for this underperformance. Following this, management revised down its targets for the fiscal year 2026, a move that immediately weighed on the stock price. At €73.75 during the session, the share reached a new four-year low, breaking the previous bottom of €77.48 recorded in 2022, a period marked by the conflict in Ukraine and rising interest rates. Over one year, the stock has now fallen nearly 35%, and almost 30% over three months. This Thursday, the CAC 40 was almost stable during the session (-0.06% at 8,151 points), as was the SBF 120 (-0.11%), which clearly isolates the punishment inflicted on the diagnostic specialist's stock.

Technical Analysis Highlights Extreme Overselling

From a technical standpoint, today's plunge has driven the share price well below the lower boundary of the Bollinger Bands, located at €88.40. The gap with this limit is significant, with the stock trading more than 14 euros below, which constitutes a signal of extreme overselling according to this indicator. The RSI, at 39, confirms this bearish tension as it approaches the conventional overselling zone set at 30. The share price is also significantly distanced from all of its moving averages: the MM50 stands at €93.19 and the MM200 at €107.92, representing respective gaps of more than 20% and 31%. The former support of €88.75, corresponding to the previous day's close, was clearly breached downwards, with no intermediate technical level appearing to slow the movement. The next financial communication milestone is scheduled for July 28, the date of publication of the 2026 half-year results.